Dr. Ron Babecoff, D.V.M. – Founder, President and CEO
Dr. Babecoff co-founded BiondVax in 2003, and has led the Company as its President and CEO since its inception. Prior to the founding of BiondVax, Dr. Babecoff had worked for 10 years in marketing and business development in the pharmaceutical industry.
In his last position as Marketing Manager at Omrix Biopharmaceuticals Ltd., Dr. Babecoff was responsible for marketing, sales training, public relations, and new product development. Some significant projects that Dr. Babecoff was then involved in include identifying West Nile Fever treatments and building cooperation with the US NIH, and forming alliances with leading international pharmaceutical companies.
Dr. Babecoff holds a D.V.M. degree from the University of Liège (ULg), Belgium and a Master of Entrepreneurship and Innovation (MEI) from the Swinburne University of Technology of Melbourne, Australia.
Dr. Tamar Ben-Yedidia – Chief Scientific Officer
Dr. Tamar Ben-Yedidia has more than 15 years of experience in the field of Immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd, BTG (Rehovot), working on the development of a recombinant Hepatitis-B vaccine.
She joined the Weizmann Institute of Science in 1994, and under the auspices of Prof. Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza. She continued this work when she left the Weizmann Institute in 2004 to join BiondVax.
Dr. Ben-Yedidia was involved in two European Consortium projects related to evaluation of different approaches for vaccination in which leading laboratories in the field participated. Dr. Ben-Yedidia is often invited to address conferences around the world and is widely published, with numerous refereed articles and invited reviews in various renowned scientific journals.
Dr. Ben-Yedidia received her Ph.D. from the Weizmann Institute after completion of her doctoral thesis entitled “A Peptide-Based Vaccine Against Influenza”.
Uri Ben-Or, CPA, MBA - Vice President, Finance
Mr. Ben-Or brings over a decade of broad experience in corporate finance, accounting, M&A transactions, IPO’s and operations. He provides his services to BiondVax through CFO Direct, a company which he founded and is the Chief Executive Officer. Prior to founding CFO Direct he served as the VP Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks, where he led all the corporate finance activities, fund raising and legal aspects of the company. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PricewaterhouseCoopers.
Mr. Ben-Or holds a BA degree in Business from the College of Administration, and a MBA degree from the Bar Ilan University. He is a Certified Public Accountant.
Dr. Tanya Gottlieb – Business Development
Tanya has over two decades of experience in scientific research and communication. She is an expert in cellular and molecular biology, cancer research and genetics. She has worked in leading laboratories, had her research published in top journals, including Cell and Science, and has been awarded several prestigious fellowships and grants.
Before joining BiondVax Tanya founded and was the CEO for 7 years of a successful business, Gottlieb Scientific Communication, with clients in industry, the medical profession and academia in Israel and abroad. Her consulting services helped clients reach a wider audience, receive funding and advance in their careers.
Tanya received her BA and PhD degrees from Cambridge University in the UK and completed postdoctoral studies at the Weizmann Institute in Israel and at the Fred Hutchinson Center in the USA.
